Newsroom

June 2022

• Ad hoc release Jun 21, 2022

  Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

  Ad hoc announcement pursuant to Art. 53 LRBasel, June 21, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding…
• Press release Jun 17, 2022

  Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically

  Nearly all children with two and three copies of the SMN2 gene treated presymptomatically achieved age-appropriate milestones, including sitting, standing and walking. All children were free of…
• 
  Story Jun 17, 2022 Access to Healthcare

  Sickle cell screening urged for newborns in Africa

  Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.

• Press release Jun 17, 2022

  Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

  Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced…
• Press release Jun 16, 2022

  New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity

  COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband…
• 
  Story Jun 14, 2022 Discovery

  A shared mission to take on the “impossible” in cancer research

• 
  Story Jun 13, 2022 Access to Healthcare

  Prostate Cancer: A collective commitment to serving underserved communities

  Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.

• Press release Jun 12, 2022

  Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

  In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…
• Press release Jun 07, 2022

  Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

  Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
• Press release Jun 06, 2022

  Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

  Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
• Press release Jun 03, 2022

  New Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer

  Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
• Press release Jun 03, 2022

  New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer

  Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…